An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Merestinib (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 11 Jan 2018 Status changed from not yet recruiting to recruiting.
- 13 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.